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Abstract
Introduction Matrix metalloproteinase 12 (MMP12) is a
proteolytic enzyme responsible for cleavage of plasminogen to
angiotensin, which has an angiostatic effect. Using data from a
population-based case–control study conducted among
Chinese women in Shanghai, we evaluated the association of
breast cancer risk and survival with two common polymorphisms
in the MMP12  gene: A-82G in the promoter region and
A1082G in exon, resulting in an amino acid change of
asparagine to serine.
Methods Included in the study were 1,129 cases and 1,229
age-frequency-matched population controls. Breast cancer
patients were followed up to determine the intervals of overall
survival and disease-free survival.
Results The frequencies of the G allele in the A-82G and
A1082G polymorphism among controls were 0.029 and 0.107,
respectively. There were no associations between MMP12
polymorphisms and breast cancer risk. Patients with the AG or
GG genotype of the A1082G polymorphism showed poorer
overall survival (though the difference was not statistically
significant) than patients with the AA genotype (hazard ratio
1.36, 95% CI 0.92 to 2.00).
Conclusion This result suggests that MMP12  A1082G
polymorphism may be related to prognosis in breast cancer
patients. Additional studies with larger sample sizes are
warranted.
Introduction
Matrix metalloproteinases (MMPs) are a family of zinc-depend-
ent proteolytic enzymes that are involved in tumor angiogen-
esis, migration, and invasion as well as the regulation of
immune surveillance [1,2]. With a few exceptions, the expres-
sion and activity of MMPs are increased in almost every type
of human cancer and are correlated with advanced tumor
stage, increased invasion and metastasis, and shortened sur-
vival [2,3]. In transplantation assays, relatively benign cancer
cells acquire malignant properties when the expression of cer-
tain MMPs is up-regulated. Conversely, highly malignant cells
become less aggressive when the expression or activity of cer-
tain MMPs is reduced [2].
Substrates of MMP12 are various extracellular matrix and non-
extracellular-matrix proteins [4]. MMP12 may inhibit angiogen-
esis through cleavage of plasminogen and collagen XVIII,
resulting in the generation of angiostatin and endostatin, which
have an angiostatic effect [2,5,6]. On the other hand, MMP12
may promote angiogenesis by cleaving structural components
of the extracellular matrix, such as collagen type IV and fibrin
[2]. It has been shown that increased expression of MMP12
may reflect a favorable prognosis in a few cancers [2].
A-82G polymorphism is located on the promoter region of the
MMP12 gene where the transcription factor activator protein
1 (AP1) binds. The A allele is associated with a higher binding
affinity for AP1, resulting in higher MMP12 promoter activity in
vitro [7]. A study showed that the A allele was associated with
AP = activator protein; CI = confidence interval; ER = estrogen receptor; HR = hazard ratio; MMP = matrix metalloproteinase; PR = progesterone 
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smaller coronary artery luminal diameter in diabetic patients
treated with percutaneous transluminal coronary angiography
and stent implantation [7]. In another study, however, no asso-
ciation was found with risk of coronary aneurysm [8]. A1082G
polymorphism is located on the coding region of the hemo-
pexin domain that is responsible for MMP12 activity. The sub-
stitution of the G allele for the A allele results in an amino acid
change from asparagine (Asn) to serine (Ser) in codon 357.
The functional significance of this single nucleotide polymor-
phism, however, has not been clearly determined. In this study,
we evaluated the association of these two common polymor-
phisms of the MMP12 gene with breast cancer risk and sur-
vival in the Shanghai Breast Cancer Study.
Materials and methods
Study participants and design
The Shanghai Breast Cancer Study is a population-based
case-control study conducted in urban Shanghai. Detailed
study design and data collection procedures have been
described elsewhere [9]. Briefly, cases were permanent
Shanghai residents between the ages of 25 and 64 years who
were newly diagnosed with breast cancer between August
1996 and March 1998. Through a rapid case ascertainment
system, supplemented by the population-based Shanghai
Cancer Registry, 1,602 eligible breast cancer patients were
identified, and 1,459 (91.1%) completed in-person interviews
using a structured questionnaire. The initial cancer diagnoses
for all patients were confirmed by two senior pathologists
through a review of pathological slides. Information about clin-
ical cancer characteristics, including TNM (tumor, node,
metastasis) stage, treatment for cancer, and estrogen recep-
tor (ER) and progesterone receptor (PR) status, was obtained
by medical record review using a standard protocol. The major
reasons for nonparticipation were refusal (109 cases; 6.8%),
death before the patient could be interviewed (17 cases;
1.1%), and our inability to locate the patient (17 cases; 1.1%)
Eligible controls were randomly selected from the Shanghai
Resident Registry, which contains demographic information
for all residents of urban Shanghai, and were frequency-
matched on age by 5-year intervals to the predetermined age
distribution of the cases reported to the Shanghai Cancer
Registry from 1990 to 1993. Of the 1,734 eligible controls,
1,556 (90.3%) completed interviews. The major reasons for
nonparticipation of the eligible controls were refusal (166 con-
trols, 9.6%) or death or a prior cancer diagnosis (2 controls,
0.1%).
The structured questionnaire used for this study included
information on demographic factors, menstrual and reproduc-
tive history, hormone use, previous disease history, family his-
tory of cancer, physical activity, tobacco and alcohol use, and
a quantitative food-frequency questionnaire. All participants
were measured for current weight, circumferences of the waist
and hips, and sitting and standing height. In addition to the in-
person interviews and anthropometric measurement, 10 ml
blood samples were collected from 1,193 (82%) cases and
1,310 (84%) controls. These samples were processed on the
same day and stored at -70°C.
The methodology for the follow-up of cancer cases was
described previously [10]. All 1,459 cancer patients were fol-
lowed through January 2003 with active follow-up and record
linkage to the death certificates of the Vital Statistics Unit of
the Shanghai Center for Disease Control and Prevention. In all,
1,290 (88.4%) patients successfully completed the follow-up
interview either in person (n = 1,241; 85%) or by telephone (n
= 49; 3.4%) between March 2000 and December 2002.
Among them, 197 patients were deceased. Through inter-
views with patients – or, for deceased patients, next of kin –
information on disease progress, recurrence of cancer, quality
of life, and cause of death (if the patient had died) was
obtained. For the remaining 169 participants, who could not
be contacted in person or by phone, linkage to the death cer-
tificates was completed in June 2003. Forty deaths were iden-
tified through the linkage, and information on the date of death
and cause of death was obtained. The remaining 126 subjects
who had no match in the death registry were assumed to be
alive on December 30, 2002, 6 months before the linkage in
order to allow for a possible delay of entry of the death certifi-
cates into the registry. Four subjects had insufficient informa-
tion for the record linkage and were excluded from survival
analysis. Finally, 1,129 cases and 1,229 controls were
included in the case-control comparison and and 1,125 cases
were included in the survival analysis
Genotyping methods
Genomic DNA was extracted from buffy coat fractions using a
Puregene® DNA Purification kit (Gentra Systems, Minneapo-
lis, MN, USA) following the manufacturer's protocol. DNA con-
centration was measured by PicoGreen® dsDNA Quantitation
Kit (Molecular Probes, Eugene, OR, USA). The allelic discrim-
ination of the MMP12 gene A-82G and A1082G polymor-
phisms were assessed with the ABI PRISM 7900 Sequence
Detection Systems (Applied Biosystems, Foster City, CA,
USA), using the fluorogenic 5' nuclease assay with primers
and probes obtained from ABI (Assay ID: C_15880589_10
and C_785907_10). PCR was performed in a total volume of
5 µl, which contained 2.5 ng DNA, 1 × TaqMan Universal PCR
Master Mix, each primer at 900 nM, and each probe at 200
nM. The thermal cycling conditions were as follows: 95°C for
10 min to activate the AmpliTaq Gold enzyme, followed by 40
cycles of 92°C for 15s and 60°C for 1 min. The fluorescence
level was measured with an ABI PRISM 7900HT Sequence
Detector (Applied Biosystems), resulting in clear identification
of three genotypes.
The laboratory staff was blind to the identity of the subjects.
Quality control samples were included in the genotyping
assays. Each 384-well plate contained four water, eight CEPHAvailable online http://breast-cancer-research.com/content/7/4/R506
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1347-02 DNA, eight blinded quality control samples, and
eight unblinded quality control samples. The concordances for
the blinded samples were 98% for A-82G and 100% for
A1082G polymorphisms, respectively. Genotypes for poly-
morphisms of A-82G in the MMP12 gene were successfully
determined for 1,118 cases and 1,223 controls and those of
A1082G for 992 cases and 976 controls.
Statistical methods
The χ 2 test and t-test were used for comparing characteristics
of cases and controls. Minor genotypes AG or GG of A-82G
and A1082G were combined in stratified analysis because of
the small number of subjects in each category. Odds ratios
and 95% confidence intervals (CIs) were derived using uncon-
ditional logistic regression models. To evaluate the association
Table 1
Comparisons of participants with MMP12 genotype information.
Participant characteristics Casesa (N = 1,129) Controlsa (N = 1,229) Pb
Demographic factors
Age (years) 47.6 ± 8.0 47.2 ± 8.7 0.20
Education (% high school or more) 43.4% 43.1% 0.89
Reproductive risk factors
Age (years) at menarche 14.5 ± 1.6 14.7 ± 1.7 <0.01
Age (years) at menopausec 48.2 ± 4.7 47.5 ± 4.9 0.04
Age (years) at first live birthd 26 ± 4.1 26.0 ± 3.8 <0.01
Other risk factors
Breast cancer among first-degree relatives (%) 3.4 2.4 0.11
Ever had breast fibroadenoma (%) 9.7 5.1 <0.01
Body mass index (kg/m2) 23.5 ± 3.4 23.2 ± 3.4 0.03
Waist-to-hip ratio 0.81 ± 0.06 0.80 ± 0.06 <0.01
Physically active during past 10 years (%) 19.3 25.7 <0.01
aValues are presented as means ± standard deviations unless otherwise noted.
bCalculated from the t-test for continuous variables and the χ 2 test for categorical variables. cAmong postmenopausal women. dAmong parous 
women.
Table 2
Association of MMP12 A-82G and A1082G polymorphisms with breast cancer risk
MMP12 genotype Cases Controls Crude OR (95% CI) Adjusted ORa (95% CI)
No. (%) No. (%)
A-82G
AA 1063 (95.1) 1153 (94.3) 1.0 1.0
AG 51 (4.6) 69 (5.6) 0.9 (0.6–1.2) 0.9 (0.6–1.3)
GG 4 (0.3) 1 (0.1)
A1082G (Asn357Ser)
AA 739 (80.2) 784 (80.3) 1.0 1.0
AG 159 (17.2) 175 (17.9) 1.0 (0.8–1.3) 1.0 (0.8–1.3)
GG 24 (2.6) 17 (1.8)
Presence of any minor genotypesb
No 687 (75.4) 731 (75.4) 1.0 1.0
Yes 224 (24.6) 239 (24.6) 1.0 (0.8–1.2) 1.0 (0.8–1.2)
aAdjusted for age, education, age at menarche, menopausal status, age at menopause, age at first live birth, waist-to-hip ratio, and physical activity 
during past 10 years. bAG/GG genotypes for A-82G and AG/GG genotype for A1082G polymorphisms. CI, confidence interval; OR, odds ratio.Breast Cancer Research    Vol 7 No 4    Shin et al.
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of MMP12 with survival, Cox proportional hazard models were
applied after adjusting for age, TNM stages, and ER/PR sta-
tus. The proportional hazard assumption of the Cox model was
examined by graphic evaluation of Schoenfeld's residual plot.
All P values presented in this paper are two-sided. SAS soft-
ware was used for statistical analysis (version 9.1; SAS Insti-
tute, Cary, NC, USA).
Results
The distribution of demographic characteristics and known
breast cancer risk factors of the cases and controls are pre-
sented in Table 1. Consistent with our previous reports [9,11],
reproductive risk factors such as early menarche, late meno-
pause, and late age at the first live birth were related to
increased breast cancer risk. Cases were also more likely than
controls to have higher body mass index (BMI), waist-to-hip
ratio, or history of breast fibroadenomas, and were less likely
to have exercised regularly during the preceding 10 years. The
case-control difference was not statistically significant in age
and education.
The distributions of MMP12 A-82G and A1082G genotypes
are shown in Table 2. In the controls, the genotype frequency
of the A-82G polymorphism did not deviate from the Hardy–
Weinberg equilibrium, but that of the A1082G genotype devi-
ated marginally (P = 0.05). In the cases, the genotype frequen-
cies of both polymorphisms deviated from the Hardy–
Weinberg equilibrium; this deviation was not likely to have
been due to a laboratory error, because the concordances for
the quality-control samples were more than 98%. Small num-
bers of subjects in the GG genotypes of both polymorphisms
would be a possible explanation for this deviation. The fre-
quencies of the minor G allele of A-82G (0.029 for controls
and 0.026 for cases) were substantially lower than those pre-
viously reported for Caucasian populations, which ranged
from 0.11 to 0.19 [7,8,12,13], whereas the minor allele fre-
quencies of A1082G (0.107 for controls and 0.112 for cases)
were higher than in one previous report of 0.05 [12]. In
agreement with an earlier report [12], we found that these two
polymorphisms are not in linkage disequilibrium [14].
Table 3
Association of MMP12 polymorphisms with clinical stage and ER/PR status in breast cancer patients
MMP12 genotype
TNM stage No. (%)
Analyzed according to stage of cancer 0, I, or II III or IV P
A-82G
AA 876 (95.1) 113 (93.4) 0.42
AG/GG 45 (4.9) 8 (6.6)
A1082G (Asn357Ser)
AA 606 (80.5) 81 (79.4) 0.80
AG/GG 147 (19.5) 21 (20.6)
Presence of any minor genotypesa
No 563 (75.6) 74 (74.0) 0.73
Yes 182 (24.4) 26 (26.0)
Analyzed according to ER/PR status  ER+/PR+ No. (%) ER-/PR- No. (%) ER+/PR- or ER-/PR+ No. (%)
A-82G
AA 401 (97.1) 188 (93.5) 144 (95.4) 0.11
AG/GG 12 (2.9) 13 (6.5) 7 (4.6)
A1082G (Asn357Ser)
AA 251 (77.0) 145 (84.8) 102 (83.6) 0.07
AG/GG 75 (23.0) 26 (15.2) 20 (16.4)
Presence of any minor genotypesa
No 238 (74.1) 133 (78.2) 96 (79.3) 0.41
Yes 83 (25.9) 37 (21.8) 25 (20.7)
aAG/GG genotypes for A-82G and AG/GG genotype for A1082G polymorphisms. ER, estrogen receptor; PR, progesterone receptor; TNM, 
tumor, node, metastasis.Available online http://breast-cancer-research.com/content/7/4/R506
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Overall, there were no associations of breast cancer risk with
either A-82G or A1082G polymorphisms alone or in combina-
tion. The genotype association did not differ by age (<45 years
vs ≥  45 years old at the time of diagnosis), menopausal status,
or family history of breast cancer (data not shown).
The frequencies of minor genotypes of both polymorphisms
were not significantly higher among patients with an advanced
stage of breast cancer, nor did they differ by ER/PR status
(Table 3).
The association of two polymorphisms of the MMP12 gene
with breast cancer survival and disease-free survival are pre-
sented in Table 4 and Fig. 1. Patients who had the AG or GG
genotypes of A1082G showed poorer overall survival than
patients who had the AA genotype (hazard ratio (HR) 1.36,
95% CI 0.92 to 2.00). Compared with those who had only the
Table 4
Association of MMP12 A-82G and A1082G polymorphism with survival in 1,125 breast cancer patients
MMP12 genotype Events/subjects 5-year survival rate (%) Crude HR (and 95% CI) Adjusted HRa (and 95% CI)
Overall survival 
A-82G
AA 173/1059 84.4 1.0 1.0
AG/GG 10/55 81.4 1.14 (0.60–2.16) 1.06 (0.56–2.00)
AG 9/51 82.0
GG 1/4 75.0
A1082G (Asn357Ser)
AA 108/738 86.0 1.0 1.0
AG/GG 34/181 81.0 1.33 (0.90–1.95) 1.36 (0.92–2.00)
AG 32/157 79.4
GG 2/24 91.7
Presence of any minor genotypesb
No 99/686 86.3 1.0 1.0
Yes 43/222 80.4 1.40 (0.98–2.00) 1.42 (0.99–2.04)
Disease-free survival 
A-82G
AA 224/1059 78.8 1.0 1.0
AG/GG 10/55 81.7 0.87 (0.46–1.64) 0.80 (0.42–1.51)
AG 9/51 82.3
GG 1/4 75.0
A1082G (Asn357Ser)
AA 151/738 79.5 1.0 1.0
AG/GG 38/181 78.8 1.04 (0.73–1.49) 1.07 (0.74–1.52)
AG 35/157 77.5
GG 3/24 87.5
Presence of any minor genotypesb
No 142/686 79.3 1.0 1.0
Yes 47/222 78.7 1.04 (0.75–1.45) 1.06 (0.76–1.47)
aAdjusted for age, TNM stage, and ER/PR status. bAG/GG genotypes for A-82G and AG/GG genotype for A1082G polymorphisms. CI, 
confidence interval; ER, estrogen receptor; HR = hazard ratio; PR, progesterone receptor; TNM, tumor, node, metastasis.Breast Cancer Research    Vol 7 No 4    Shin et al.
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AA genotypes in both A-82G and A1082G polymorphisms,
patients who had one or more of the minor genotypes in these
polymorphisms showed a poorer overall survival (HR 1.42,
95% CI 0.99 to 2.04). Our data did not suggest an associa-
tion between MMP12 gene polymorphisms and disease-free
survival.
Discussion
This study suggests that two common polymorphisms (A-82G
and A1082G) of the MMP12  gene may not be related to
breast cancer risk. The A1082G polymorphism, however, may
be associated with the prognosis for breast cancer patients.
The association with survival seems to be independent of
other clinical prognostic factors such as cancer stage or ER/
PR status.
Yang and colleagues reported that overexpression of MMP12
in tumors correlated with increased survival and decreased
tumor neovascularization in colorectal cancer patients [15].
Similarly, Kerkelä and colleagues reported that MMP12
expressed in macrophages in the tumor site correlated with
well-differentiated cancer cells [16]. MMP12 is expressed in
breast tissue and may exert its protective effect through the
cleavage of plasminogen to angiostatin and of collagen XVIII
to endostatin [17-19]. In addition, MMP12 is also involved in
the cleavage of domain D1 of urokinase-type plasminogen
activator cellular receptor, which is responsible for cell migra-
tion during tumor invasion and angiogenesis [20]. The A-82G
polymorphic site is the binding site of AP1, and the A allele is
related to increased MMP12 activity [3,7]. Given the func-
tional significance of this single nucleotide polymorphism and
the role of MMP12 in breast carcinogenesis, we hypothesized
that this single nucleotide polymorphism may be related to
breast cancer risk and survival. Our findings, however, do not
support this hypothesis. The much lower frequency of the
minor G allele in our study population than in Caucasian pop-
ulations [7,8,12,13] substantially reduces the statistical
power. Indeed, we had only 51% power to detect 30%
decreased risk of AG or GG genotypes, assuming a type I
error of 0.05 [21].
A1082G polymorphism of the MMP12 gene results in a sub-
stitution of amino acid Ser for Asn in codon 357. The function
of this polymorphism has not yet been determined; however,
the substitution of a hydroxylic amino acid (Ser) for an acidic
amino acid (Asn) may affect the activity of the enzyme [12]. In
our study, the AG or GG genotypes of A1082G polymorphism
were associated with poor prognosis of breast cancer
patients. This result was prominent only in overall survival, but
not in disease-free survival. The information on overall survival,
however, is likely to be more accurate than that on disease-
free survival, because information on disease progress and
recurrence was collected by interviews with patients, or kin of
deceased patients, rather than by reviewing medical records.
Further evaluation of this association in other populations is
required.
Our study has several strengths. First, the population-based
study design and the high participation rate minimize potential
selection bias. Second, the homogeneous ethnicity of this
population (Han Chinese) minimizes possible population strat-
ification [22]. Third, including comprehensive lifestyle and clin-
ical information makes it possible to consider potential
confounding and interactive effects in data analysis.
Conclusion
Our study suggests breast cancer risk may not be associated
with the A-82G and A1082G polymorphisms in the MMP12
Figure 1
Overall survival among breast cancer patients analyzed according to  A1082G polymorphism and combined A-82G and A1082G polymor- phisms of the MMP12 gene and P values for survival curves derived  using a log-rank test Overall survival among breast cancer patients analyzed according to 
A1082G polymorphism and combined A-82G and A1082G polymor-
phisms of the MMP12 gene and P values for survival curves derived 
using a log-rank test. (a) Patients carrying the AG or GG genotypes at 
the A1082G polymorphism had a lower overall survival rate than those 
who had the AA genotype. (b) Patients carrying either of the minor gen-
otypes (AG or GG) in either A-82G or A1082G polymorphisms had a 
lower overall survival rate than those who had the AA genotype for both 
A-82G and A1082G polymorphisms.Available online http://breast-cancer-research.com/content/7/4/R506
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gene. The minor G allele in the A1082G polymorphism,
however, may be related to poorer prognosis for breast cancer
patients. This is the first report on the association of the
MMP12 gene polymorphism with breast cancer risk and sur-
vival, and the results need to be confirmed in other large-scale
studies.
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